Entity

Time filter

Source Type

Salt Lake City, UT, United States

Brooks B.D.,Wasatch Microfluidics | Brooks A.E.,University of Utah | Brooks A.E.,North Dakota State University
Advanced Drug Delivery Reviews | Year: 2014

With multidrug resistant bacteria on the rise, new antibiotic approaches are required. Although a number of new small molecule antibiotics are currently in the development pipeline with many more in preclinical development, the clinical options and practices for infection control must be expanded. Biologics and non-antibiotic adjuvants offer this opportunity for expansion. Nevertheless, to avoid known mechanisms of resistance, intelligent combination approaches for multiple simultaneous and complimentary therapies must be designed. Combination approaches should extend beyond biologically active molecules to include smart controlled delivery strategies. Infection control must integrate antimicrobial stewardship, new antibiotic molecules, biologics, and delivery strategies into effective combination therapies designed to 1) fight the infection, 2) avoid resistance, and 3) protect the natural microbiome. This review explores these developing strategies in the context of circumventing current mechanisms of resistance. © 2014 Elsevier B.V. Source


Brooks B.D.,Wasatch Microfluidics
Current Drug Discovery Technologies | Year: 2014

The pharmaceutical industry is experiencing comeback sales growth due in large part to the industry's R&D efforts that center on biologics drug development. To facilitate that effort, tools are being developed for more effective biologic drug development. At the forefront of this effort is epitope characterization, in particular epitope binning, primarily due to the role an epitope plays in drug function. Here we detail the financial advantages of epitope binning including (1) increased R&D productivity due to increased work in process, (2) reduced number of "dead-end"candidates, and (3) increasedability to reengineer antibodies based on the epitope. With the arrival of high throughput biosensors, this manuscript serves as a call to push epitope binning earlier in the biological drug discovery process. © 2014 Bentham Science Publishers. Source


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 329.75K | Year: 2014

DESCRIPTION (provided by applicant): Real-time label-free technologies such as surface plasmon resonance biosensors provide high-resolution information about the kinetics, affinity, stoichiometry, activity, and specificity, of two (or more) binding partners. While the application f biosensors is well established, current instrumentation has limited sampling throughput. Screens of even a fairly small chemical library (e.g., 3000-5000 compounds) require days to weeks to complete using traditional label-free instruments. Because of the quality of the data generated by SPR, drug discovery scientists are clamoring to use enhanced biosensors as a screening tool for small molecule applications; however, lack of throughput hinders their ability to move in this direction. We propose to develop a biosensor platform that has increased throughput yet maintains the data quality and ease of use to which researchers are accustomed. We will couple our novel Continuous Flow Microspotter (CFM) with an enhanced-sensitivity SPR


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.02M | Year: 2015

DESCRIPTION provided by applicant Real time label free technologies such as surface plasmon resonance biosensors provide high resolution information about the kinetics affinity stoichiometry activity and specificity of two or more binding partners While the application f biosensors is well established current instrumentation has limited sampling throughput Screens of even a fairly small chemical library e g compounds require days to weeks to complete using traditional label free instruments Because of the quality of the data generated by SPR drug discovery scientists are clamoring to use enhanced biosensors as a screening tool for small molecule applications however lack of throughput hinders their ability to move in this direction We propose to develop a biosensor platform that has increased throughput yet maintains the data quality and ease of use to which researchers are accustomed We will couple our novel Continuous Flow Microspotter CFM with an enhanced sensitivity SPR biosensor from BiOptix to enable label free screening and kinetic analsyis of small molecules and biologics In high throughput screening mode our channel integrated CFM E biosensor platform will be capable of collecting data for andgt samples in less than hours a sampling rate x faster than fastest small molecule capable label free biosensor the Biacore PUBLIC HEALTH RELEVANCE Label free real time biosensors enable the measurement of the kinetics of biomolecule binding Getting this information earlier in the drug discovery process reduces false positives identifies candidates that may have been missed improves subject matter for patent filings and increases the probability of the selected candidateandapos s eventual success Traditional label free biosensors have limited sample throughput which has restricted their use to secondary roles By combining our highly parallel microfluidic sample delivery technology with a small molecule sensitive biosensor we will enable the high throughput label free analysis of small molecules and biologics which offers significant potential for increasing the efficiency of early stage drug discovery


Patent
Wasatch Microfluidics and Rinat Neuroscience | Date: 2014-12-02

A system and method for sensing and analyzing antibody blocking interactions is described. A biosensor can be used to identify interactions between antibodies to generate interaction profiles for the antibodies. A processor can be used to assign the antibodies to one or more bins, with the antibodies sharing a common interaction profile assigned to a common bin, and each antibody only being assigned to one bin. The antibodies can be represented by displaying nodes grouped together for antibodies in a common bin. Connections between the nodes can be displayed, representing interactions between the antibodies.

Discover hidden collaborations